Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.
Curr Opin Obstet Gynecol. 2012 Aug;24(4):215-20. doi: 10.1097/GCO.0b013e328355847e.
Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual dysfunction, with estimates of prevalence approximating 10%. By definition it is a deficiency of sexual desire that causes distress. HSDD has no single cause, but physiological, psychological and socio-cultural factors underpinning female sexual desire may all be important in its development.
Medical therapeutic strategies to date have concentrated on modulation of hormone levels, particularly androgen administration, yet few products have been approved for the treatment of HSDD in developed countries. More recent medical targets have included agents with 5-hydroxytryptamine agonist activity. Psychological therapeutic approaches have been infrequently studied but concentrate on cognitive behavioural therapy.
HSDD is an evolving diagnosis, the existence of which has been questioned by some critics. Whilst HSDD remains the subject of ongoing research, its title and definition are under debate as a new edition of the Diagnostic and Statistical Manual of the American Psychiatric Association approaches publication in 2012.
性欲低下障碍(HSDD)是最常见的女性性功能障碍,其患病率估计接近 10%。根据定义,它是一种导致痛苦的性欲缺失。HSDD 没有单一的原因,但女性性欲的生理、心理和社会文化因素在其发展中都可能很重要。
迄今为止,医学治疗策略集中在调节激素水平上,特别是雄激素的应用,但在发达国家,很少有产品被批准用于治疗 HSDD。最近的医学治疗目标包括具有 5-羟色胺激动活性的药物。心理治疗方法很少被研究,但集中在认知行为疗法上。
HSDD 是一个不断发展的诊断,一些批评者对其存在提出了质疑。虽然 HSDD 仍在不断研究中,但由于美国精神病学协会的诊断和统计手册的新版本将于 2012 年出版,其名称和定义正在争论之中。